A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia

Autor: Mackay, H.J., Buckanovich, R.J., Hirte, H., Correa, R., Hoskins, P., Biagi, J., Martin, L.P., Fleming, G.F., Morgan, R., Wang, L., Polintan, R., Oza, A.M.
Zdroj: In Gynecologic Oncology April 2012 125(1):136-140
Databáze: ScienceDirect
Externí odkaz: